Merck and Isomorphic Labs team up to design cancer drug candidates with AI

Isomorphic will apply its IsoDDE design engine and Merck data to an undisclosed oncology target, for an upfront payment, milestones and tiered royalties.
Why it matters
Isomorphic Labs, the Alphabet drug-discovery company led by Demis Hassabis, is adding another large pharma partner two days after announcing a $5bn Series C. The deal pairs its IsoDDE design engine with proprietary Merck data sets, while Merck keeps preclinical and clinical development, manufacturing and commercialisation. STAT calls it only the latest such deal between a pharma giant and Isomorphic. Financial terms were not disclosed. Watch whether the collaboration produces a named candidate and when it reaches clinical trials.
Key facts
- Partners: Merck (MSD) and Isomorphic Labs
- Target: undisclosed oncology target
- Engine: Isomorphic's IsoDDE plus Merck data sets
- Terms: upfront payment, milestones, tiered royalties
- Isomorphic has an option to co-fund development